Healthcare Triangle, Inc. HCTI
Last close
0.34
2026-10-23
Market cap
$5.0M
2026-06-30 share count
52-week range
0.33 - 188.40
Valuation FY2025 figures against the last close
P/S0.4x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-152.30
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $13.9M | $11.7M | $33.2M | $45.9M | $35.3M | $31.3M | — |
| Cost of revenue | $12.0M | $8.8M | $26.4M | $34.6M | $24.7M | $22.8M | — |
| Gross profit | $1.24B | $1.07B | $1.07B | $11.3M | $10.5M | $8.6M | — |
| R&D | $536.0K | $429.0K | $799.0K | $8.1M | $5.3M | $1.7M | — |
| SG&A | $7.3M | $4.0M | $5.7M | $5.5M | $0 | $2.4M | — |
| Total operating expenses | $11.7M | $7.6M | $14.5M | $27.6M | $15.9M | — | — |
| Operating income | -$9.8M | -$4.8M | -$7.7M | -$16.3M | -$5.4M | $1.2M | — |
| Interest expense | $567.0K | $1.2M | $968.0K | $212.0K | $567.0K | $78.6K | — |
| Pre-tax income | -$9.5M | -$6.0M | -$8.7M | -$13.9M | -$5.9M | $2.6M | — |
| Income tax | — | $12.0K | $35.0K | $506.0K | $24.0K | $257.4K | — |
| Net income | -$9.5M | -$6.0M | -$8.7M | -$14.4M | -$5.9M | $2.4M | — |
| EPS, basic | -152.30 | -16,909.30 | -2.08 | -3.88 | -0.20 | 0.08 | — |
| EPS, diluted | -152.30 | -16,909.30 | -2.08 | -3.88 | -0.20 | 0.08 | — |
| Shares, diluted (wtd. avg.) | 61,873 | 353 | 4.2M | 3.7M | 29.4M | 27.9M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $7.6M | $20.0K | $1.2M | $1.3M | $1.8M | $1.4M | $974.8K |
| Receivables | $2.1M | $1.1M | $3.6M | $5.9M | $9.7M | $6.4M | — |
| Total current assets | $13.2M | $1.5M | $5.7M | $8.0M | $11.8M | $8.0M | — |
| Property, plant and equipment | $5.0K | $12.0K | $44.0K | $80.0K | $74.0K | $15.8K | — |
| Goodwill | $2.9M | — | — | $1.3M | $1.3M | — | — |
| Other intangibles | $2.8M | — | $857.0K | $4.1M | $10.5M | $2.6M | — |
| Total assets | $22.7M | $2.0M | $6.9M | $13.3M | $24.6M | $11.1M | — |
| Accounts payable | $744.0K | $2.5M | $2.0M | $1.5M | $1.9M | $4.3M | — |
| Short-term debt | $10.7M | $2.6M | $3.8M | $2.7M | $2.2M | — | — |
| Total current liabilities | $12.8M | $7.1M | $8.2M | $6.6M | $6.3M | $6.8M | — |
| Total liabilities | — | $7.1M | $8.2M | $7.2M | $8.5M | $6.8M | — |
| Retained earnings | -$43.0M | -$33.6M | -$27.6M | -$18.9M | -$2.7M | — | — |
| Total equity | $9.9M | -$5.1M | -$1.4M | $6.0M | $14.2M | $4.3M | $2.0M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$16.5M | -$1.1M | -$2.2M | -$5.4M | -$7.1M | -$734.7K | — |
| Depreciation and amortisation | $705.0K | $889.0K | $1.6M | $2.9M | $1.4M | $803.2K | — |
| Stock-based compensation | $451.0K | $87.0K | $166.0K | $257.0K | — | — | — |
| Capital expenditure | $6.0K | — | $12.0K | $40.0K | — | — | — |
| Investing cash flow | -$1.8M | — | -$12.0K | -$1.1M | -$7.6M | -$477.5K | — |
| Financing cash flow | $25.9M | -$133.0K | $2.1M | $6.1M | $15.1M | $1.6M | — |
| Buybacks | — | — | — | $141.0K | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-044671.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $31.3M | $35.3M | $45.9M | $33.2M | $11.7M | $13.9M |
| Gross profit | — | $8.6M | $10.5M | $11.3M | $1.07B | $1.07B | $1.24B |
| Net income | — | $2.4M | -$5.9M | -$14.4M | -$8.7M | -$6.0M | -$9.5M |
Recent filings and events
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Item 3.02
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Material agreement signed Item 1.01
- New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
- Unregistered share sale Item 3.02
- Regulation FD disclosure Item 7.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Material agreement signed Item 1.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 7373
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| IOT | Samsara Inc. | $26.14B | — | 29.6% |
| LDOS | Leidos Holdings, Inc. | $17.08B | 12.2x | 3.2% |
| GDDY | GoDaddy Inc. | $14.28B | 18.1x | 8.3% |
| CACI | CACI INTERNATIONAL INC /DE/ | $14.01B | 26.2x | 10.9% |
| IONQ | IonQ, Inc. | $11.91B | — | 201.9% |
| JKHY | JACK HENRY & ASSOCIATES INC | $11.40B | 23.3x | 7.1% |
| AUR | Aurora Innovation, Inc. | $9.50B | — | — |
| OTEX | OPEN TEXT CORP | $6.77B | 10.8x | 1.5% |